Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + cetuximab + imprime PGG + paclitaxel
- Development stage
- Preclinical
- Lead developer
- HiberCell
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of carboplatin, cetuximab, imprime PGG, and paclitaxel. This regimen combines platinum-based chemotherapy (carboplatin), a taxane (paclitaxel), an EGFR-targeting monoclonal antibody (cetuximab), and an immunomodulator (imprime PGG). The combination is primarily investigated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (SCCHN). Carboplatin is a platinum-based chemotherapy agent that works by binding to DNA and interfering with cell division. Paclitaxel stabilizes microtubules, preventing cell division. Cetuximab targets the epidermal growth factor receptor (EGFR), blocking cell growth signaling pathways. Imprime PGG is likely an immunomodulator that may enhance the efficacy of the other components.
02
Targets
Beyond the preview
Go deeper on carboplatin + cetuximab + imprime PGG + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + cetuximab + imprime PGG + paclitaxel.